Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

Gastric cancer (GC) is defined as the primary epithelial malignancy derived from the
stomach, and it is a complicated and heterogeneous disease with multiple risk factors …

There is an urgent need for first-line treatment options for patients with human epidermal
growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic …

Background Zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (CLDN18.
2), has shown efficacy in patients with CLDN18. 2-positive, human epidermal growth factor …

Background Evidence for the efficacy of combined PD-1 and HER2 blockade with
chemotherapy on progression-free and overall survival in HER2-positive gastro …

Background The benefit of combination neoadjuvant and adjuvant chemotherapy and
immune checkpoint inhibition in patients with locally advanced, resectable gastric or gastro …

PURPOSE To develop recommendations involving targeted therapies for patients with
advanced gastroesophageal cancer. METHODS The American Society of Clinical Oncology …

For inoperable esophageal adenocarcinoma (EAC), identifying patients likely to benefit from
recently approved immunochemotherapy (ICI+ CTX) treatments remains a key challenge …

Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …

Gastric cancer (GC) is a major health concern in many countries. GC is a heterogeneous
disease stratified by histopathological differences. However, these variations are not used to …